EB

EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research

Retrieved on: 
Tuesday, November 14, 2023
Major League Baseball, Chihuly Garden and Glass, Research, Yale University, Imagine, The Mayor, Entrepreneurship, Hope, Glass, ICON, Epidermolysis bullosa, Disease, Clinical trial, Learning, Patient, Former, FDA, Heart, EB, Humble (surname), Benaroya Hall, Stanford University, ICON PLC, MPH, MD, Doctor of Public Health, Parent, Digital health, AWS, Chief innovation officer, HSS, Pharmaceutical industry, Entertainment, Doctor of Philosophy

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Eddie Vedder played two intimate concerts in his hometown of Seattle at Benaroya Hall on October 23rd and 24th to bring support to a cause that is near to his heart – EB Research Partnership (EBRP). Alongside the emotional shows, EBRP hosted its first in-person Venture Into Cures Summit and Dinner.

Key Points: 
  • EB Research Partnership hosted the Venture Into Cures Summit alongside two Eddie Vedder shows in Seattle to support their mission of curing EB and other rare diseases.
  • EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research.
  • Founded in 2010 by a group of dedicated parents, Jill Vedder, and Eddie Vedder of Pearl Jam, EB Research Partnership (EBRP) is the largest 501(c)(3) nonprofit funding research aimed at finding a cure for Epidermolysis Bullosa (EB).
  • We can make an impact for the millions out there battling a rare disease," said Jill Vedder, Co-Founder and Chairwoman at EBRP.

debra of America Raises $600,000 at Annual Benefit; Honors Trailblazers in Epidermolysis Bullosa Community

Retrieved on: 
Friday, November 10, 2023
Medicine, Health, Courage, Research, EBS, King County Superior Court, Therapy, Epidermolysis bullosa, Blister, Disease, Abrasion (medical), 34th Independent Spirit Awards, Patient, Genetic disorder, COL7A1, U.S. FDA, FDA, Epidermolysis bullosa dystrophica, EB, Partner, DEBRA, Conference, MD, Trauma, Survival, DEB, Junctional epidermolysis bullosa (medicine), Skin, Quality of life, Georgia Aquarium, Independent Spirit Awards, Government, Life, Legislation, Superior court, Policy, Pharmaceutical industry, Nursing

Funds raised help advance EB research initiatives and directly support families and individuals living with EB.

Key Points: 
  • Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
  • At the benefit, debra honored several EB trailblazers for their research and therapeutic contributions as well as individuals living with the disease.
  • Krystal Biotech was recognized for its work in developing VYJUVEK™ (beremagene geperpavec-svdt), the first FDA-approved treatment of Dystrophic Epidermolysis Bullosa (DEB).
  • Epidermolysis Bullosa is a rare genetic disorder characterized by fragile skin that easily blisters or forms painful sores from minor friction or trauma.

BPGbio Wins 2023 BioTech Breakthrough Award for Therapeutics Platform of The Year

Retrieved on: 
Wednesday, November 8, 2023
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Drug discovery, GBM, Harvard Medical School, AstraZeneca, CIA, Netherlands Architecture Institute, Biomarker, Rare, Therapy, Government, Oak Ridge National Laboratory, United States Department of Defense, Supercomputing in India, Carcinoma, Icahn School of Medicine at Mount Sinai, HPC, Organization, SCC, Research, Prostate cancer, Glioblastoma, Liver disease, Multimedia, Medicine, Biology, EB, Neurology, Breast cancer, Pancreatic cancer, Sanofi, AI, ORNL, Mount Sinai, Patient, Epidermolysis bullosa, Sarcopenia, Pharmaceutical industry, Medical device, Neuroscience

View the full release here: https://www.businesswire.com/news/home/20231108370629/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231108370629/en/
    BPGbio named Therapeutics Platform of the Year by Biotech Breakthrough Awards program.
  • The award recognizes BPGbio’s success leveraging their NAi Interrogative Biology Platform to develop late-stage therapeutics and diagnostics for some of the most challenging diseases.
  • “We are honored that BPGbio has won the Therapeutics Platform of the Year from BioTech Breakthrough, a massive achievement for our employees and research partners.
  • BPGbio, our ‘Therapeutics Platform of the Year’ winner, is proving the value of AI in drug discovery for the future of medicine,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards.

BPGbio Highlights AI-Developed Late-Stage Therapeutics Assets at 8th Annual INV€$TIVAL Showcase in Partnership with Jefferies

Retrieved on: 
Tuesday, November 7, 2023
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Pancreatic cancer, GBM, Glioblastoma, Food, Netherlands Architecture Institute, Biomarker, Oak Ridge National Laboratory, Rare, Carcinoma, HPC, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SCC, Liver disease, Drug discovery, EB, Neurology, Parkinson's disease, Breast cancer, Partnership, Jefferies, Tumor microenvironment, AI, ORNL, TME, Epidermolysis bullosa, Sarcopenia, Medical device, Pharmaceutical industry, Frontier

BPGbio will present as part of the event’s Biotech Late Growth Stage track.

Key Points: 
  • BPGbio will present as part of the event’s Biotech Late Growth Stage track.
  • Last month, an independent medical advisory board recommended advancement into phase 2b trials for pancreatic cancer.
  • BPM31510 for pancreatic cancer has received orphan drug designation from the U.S. Food and Drug Administration.
  • This platform identifies targets, biomarkers, and drugs and assists the development team through both the developmental and clinical trial stages.

Nokia Technology Strategy 2030: emerging technology trends and their impact on networks

Retrieved on: 
Tuesday, October 31, 2023
Chief technology officer, Organization, Artificial intelligence, Growth, EB, Machine learning, XR, API, ML, AI, Global Television Network, Technology strategy, Automation, Mobile phone

Nokia’s Technology Strategy 2030 is fundamental to realizing the full potential of AI, cloud and other emerging trends with connectivity at the center enabling the adoption of these technologies

Key Points: 
  • Nokia’s Technology Strategy 2030 is fundamental to realizing the full potential of AI, cloud and other emerging trends with connectivity at the center enabling the adoption of these technologies
    Espoo, Finland – Nokia today presents its Technology Strategy 2030 that identifies trends and emerging technologies that will shape technology, networks and the world for the next seven years.
  • Nishant Batra, Chief Strategy and Technology Officer, Nokia, said: “Nokia’s Technology Strategy 2030 is a direct response to the proliferation of cutting-edge technologies over the last decade.
  • The key trends influencing Nokia’s Technology Strategy 2030 are AI, cloud continuum, metaverse, API economy, Industry 5.0, Internet of value, sustainability, and security.
  • Nokia, and the industry as a whole, must show that they understand the problems and potential, with a revitalized approach as indicated by the long-term Nokia Technology Strategy 2030.”

Eventbrite Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Other Entertainment, General Entertainment, Entertainment, Events, Concerts, Letter, Q&A, Growth, Investment, Marketing, NYSE, EB, Entrepreneurship, Video game, Eventbrite

Eventbrite, Inc. (NYSE:EB), a global events marketplace, today posted its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Eventbrite, Inc. (NYSE:EB), a global events marketplace, today posted its financial results for the third quarter ended September 30, 2023.
  • The Third Quarter Shareholder Letter can be found on Eventbrite’s Investor Relations website at https://investor.eventbrite.com .
  • “We’re proud of our strong execution in the third quarter as we achieved record take rate and revenue per ticket.
  • The webcast of the conference call can be accessed as follows:
    An archived webcast of the conference call will also be accessible on Eventbrite’s Investor Relations page, https://investor.eventbrite.com .

A New Hope for Epidermolysis Bullosa (“butterfly children”) Thanks to Novel CRISPR-Cas3 Platform

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Health, Family, Consumer, Other Health, Pharmaceutical, Stem Cells, Other Science, Research, Children, Genetics, Health Technology, Science, Medical Supplies, Gene editing, Epidermolysis bullosa, Hope, CRISPR, Skin, Blister, Trauma, Multimedia, Quality of life, Skin condition, Entrepreneurship, EB, Friction, Pain, Patient, Vaccine

View the full release here: https://www.businesswire.com/news/home/20231030362422/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231030362422/en/
    Epidermolysis bullosa is a rare genetic skin disorder characterized by highly sensitive skin that blisters and erodes with minimal friction or trauma, such as rubbing or scratching.
  • EB affects approximately 20 out of every 1 million newborns in the United States where 25,000 to 50,000 young children are living with this debilitating condition.
  • The collaborative endeavor between Healiva and C4U will focus on the development of CRISPR-Cas3 based gene therapy for EB.
  • “By utilizing its proprietary CRISPR-Cas3 technology, a new generation of gene editing technology, C4U’s focus is to develop alternative and complete cures to genetic diseases.

Onconova Expands Leadership Team with Two Key Appointments

Retrieved on: 
Tuesday, October 24, 2023
Drug development, Research, Bone marrow, Ovarian cancer, Nottingham Trent University, Medicine, Internal medicine, Bachelor, Biomedical sciences, George Washington School, Pediatric Hematology and Oncology, Medical Affairs Bureau, Pharmacy, European Society for Clinical Investigation, Pharmaceutical medicine, University of Zimbabwe, Postgraduate diploma, Epidermolysis bullosa, University, NDA, Cancer, Therapy, Patient, Myelodysplastic syndrome, Merrimack Pharmaceuticals, GSK plc, Medication, CMO, Nottingham, Johns Hopkins School of Medicine, King's College London, University of Surrey, IND, Consultant, Outline of health sciences, Patent, Rare, Inflammation, R, EB, Johnson & Johnson, Pharmaceutical industry, Nursing, Biotechnology, Science, Hematology, Honours degree

NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Key Points: 
  • Both are accomplished experts in their fields and bring significant and wide expertise in drug development.
  • I look forward to working with my colleagues at Onconova and our clinical collaborators to contribute to our mission of bringing narazaciclib and rigosertib to patients with cancer.
  • He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.
  • Prior to that, she held various leadership roles as Medical Director or Associate Medical Director, as well as roles in Investigator Research and Medical Affairs at Celgene International.

NJOY Brings Sweeping Litigation Against Illicit Disposable Vapor Manufacturers

Retrieved on: 
Thursday, October 19, 2023
Public Policy, Government, Other Manufacturing, Tobacco, Other Policy Issues, Consumer Electronics, Technology, Manufacturing, Retail, NJOY, FDA, AB InBev, Complaint, Sale, Helix, Horizon, Food, ABI, United States Customs Service, Regulation of tobacco by the U.S. Food and Drug Administration, Research, PM, Philip Morris USA Inc. v. Williams, Marlboro, City, District court, Marketing, EB, John Middleton Co., Central District, Smoker, Education Act, Investment, General counsel, Lanham Act, Heated tobacco product, MST, Defendant, Cronos, Altria

Altria Group, Inc. (Altria) announces today its operating company NJOY, LLC (NJOY) has filed sweeping litigation against 34 foreign and domestic manufacturers, distributors and online retailers of illicit disposable e-vapor products that are unlawfully marketed and sold in the State of California and elsewhere.

Key Points: 
  • Altria Group, Inc. (Altria) announces today its operating company NJOY, LLC (NJOY) has filed sweeping litigation against 34 foreign and domestic manufacturers, distributors and online retailers of illicit disposable e-vapor products that are unlawfully marketed and sold in the State of California and elsewhere.
  • The suit seeks a nation-wide injunction against the import, marketing and sale of these illicit products and significant compensatory and punitive damages.
  • “Today there are two markets – one for those who play by the rules and one for those who flagrantly ignore them.
  • NJOY may add additional manufacturers, distributors and retailers to this complaint and will consider further litigation activity.

Eventbrite Announces Date of Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 18, 2023
Security, Data Management, Technology, Public Relations, Investor Relations, Events, Concerts, Communications, General Entertainment, Apps, Applications, Other Entertainment, Media, Software, Entertainment, Digital Marketing, Networks, Mobile, Wireless, NYSE, EB, Cryptocurrency, Computer data storage

Eventbrite, Inc. (NYSE: EB), a global events marketplace, announced that it will release its financial results for the third quarter ended September 30, 2023, after the market closes on Wednesday, November 1, 2023.

Key Points: 
  • Eventbrite, Inc. (NYSE: EB), a global events marketplace, announced that it will release its financial results for the third quarter ended September 30, 2023, after the market closes on Wednesday, November 1, 2023.
  • An archived webcast of the conference call will be accessible on Eventbrite’s Investor Relations page, https://investor.eventbrite.com .